Detalles de la búsqueda
1.
Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care.
Eur J Haematol
; 109(6): 749-754, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36066204
2.
Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups.
Eur J Haematol
; 106(4): 546-554, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33471414
3.
Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14).
Am J Hematol
; 96(8): 925-933, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33901326
4.
Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?
Eur J Haematol
; 103(6): 588-596, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31487754
5.
Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma.
Eur J Haematol
; 103(3): 247-254, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31231833
6.
Response to Caravita di Toritto and Rago.
Eur J Haematol
; 110(2): 224-225, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36300846
7.
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register.
Eur J Haematol
; 99(3): 216-222, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28544116
8.
Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy.
Am J Hematol
; 96(11): E443-E446, 2021 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34524709
9.
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
Br J Haematol
; 164(5): 684-93, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24313224
10.
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients.
Eur J Haematol
; 92(1): 19-25, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24118547
11.
Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden.
Cancer Med
; 13(8): e7048, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38651177
12.
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.
Cancers (Basel)
; 16(5)2024 Feb 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38473382
13.
A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results from a Swedish retrospective analysis.
Acta Haematol
; 130(1): 7-15, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23363691
14.
Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma.
Cancer Med
; 12(22): 20736-20744, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37921243
15.
Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma.
PLoS One
; 10(9): e0138248, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26378933
16.
The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.
PLoS One
; 9(7): e101819, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25003848
Resultados
1 -
16
de 16
1
Próxima >
>>